Xylasol 20 mg/ml, solution for injection for cattle, horses, dogs and cats

Authorised

- Xylazine hydrochloride

Product identification

Medicine name:
Xylasol 20 mg/ml, solution for injection for cattle, horses, dogs and cats
Xylasol 20 mg/ml, oplossing voor injectie voor runderen, paarden, honden en katten

Active substance:
Xylazine hydrochloride

Target species:
Cattle
Horse
Dog
Cat

Route of administration:
Intramuscular use
Intravenous use
Subcutaneous use

Product details

Active substance and strength:
Xylazine hydrochloride
23.31 milligram(s) / 1.00 millilitre(s)

Pharmaceutical form:
Solution for injection

Withdrawal period by route of administration:
Intramuscular use:

- **Cattle**
  - Milk. no withdrawal period — Should be 0 days
  - Meat and offal. 1 day
- **Horse**
  - Milk. no withdrawal period — Should be 0 days
  - Meat and offal. 1 day

Intravenous use:

- **Cattle**
  - Milk. no withdrawal period — Should be 0 days
  - Meat and offal. 1 day
- **Horse**
  - Milk. no withdrawal period — Should be 0 days
  - Meat and offal. 1 day

Subcutaneous use:

- **Cattle**
  - Milk. no withdrawal period — Should be 0 days
  - Meat and offal. 1 day
- **Horse**
  - Milk. no withdrawal period — Should be 0 days
  - Meat and offal. 1 day

Anatomical therapeutic chemical veterinary (ATCvet) codes:
QN05CM92

Legal status of supply:
Veterinary medicinal product subject to veterinary prescription

Authorisation status:
Valid

Authorised in:
Netherlands

Package description:
Cardboard box containing 1 vial (uncoloured glass type II, closed with bromobutyl rubber stopper, secured with aluminium cap) filled with 50 ml
Cardboard box containing 1 vial (uncoloured glass type II, closed with bromobutyl rubber stopper, secured with aluminium cap) filled with 25 ml
Cardboard box containing 1 vial (uncoloured glass type II, closed with bromobutyl rubber stopper, secured with aluminium cap) filled with 10 ml

Additional information

Entitlement type:
Marketing Authorisation

Legal basis of product authorisation:

Generic application (Article 13(1) of Directive No 2001/82/EC)

Marketing authorisation holder:
CP-Pharma Handelsgesellschaft mbH

Marketing authorisation date:
6/04/2012

Manufacturing sites for batch release:
CP-Pharma Handelsgesellschaft mbH

Responsible authority:
Medicines Evaluation Board

Authorisation number:
REG NL 108964

Date of authorisation status change:
25/01/2022

Reference member state:
Netherlands

Procedure number:
NL/V/0158/001

Concerned member states:
Austria Denmark Finland France Germany Hungary Norway Spain Sweden

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Combined File of all Documents

English (PDF)

Published on: 21/06/2022

Download

108964 - par.pdf